The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia

Recenti Progressi in Medicina

Volumn 87, Issue 12, 1996, Pages 582-585

  Lissoni, Paolo ^a   Tancini, Gabriele ^a   Barni, Sandro ^a   Paolorossi, Franco ^a   Rossini, Fausto ^a   Maffé, Pierfranco ^a   Di Bella, Luigi ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Hematology; Melatonin; Platelets; Thrombocytopenia

Indexed keywords

MELATONIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIESIS; HUMANS; MALE; MELATONIN; MIDDLE AGED; PLATELET COUNT; THROMBOCYTOPENIA;

EID: 0030473928     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Iguchi H, Kato KI, Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27-9.
2. Arendt J. Melatonin. Clin Endocrinol 1988; 29: 205-29.
3. Dubocovich ML. Functional and molecular melatonin receptor subtypes. 2nd Locarno Meeting on Neuroendocrinoimmunology, p. 14. Locarno 1996; May 5-8.
4. Carlberg C, Wiesenberg I, Schräder M. Nuclear signalling of melatonin. 2nd Locarno Meeting on Neuroendocrinoimmunology, p. 16. Locarno 1996; May 5-8.
5. Blask DE. Neuroendocrine aspects of circadian pharmacodynamics. In: Circadian Cancer Therapy, pp. 43-59. Hrushesky WJM (Ed). CRC Press, Boca Raton, Ann Arbor, London, Tokyo, 1994.
6. Villa S, Lissoni P, Fraschini F. In vitro effects of melatonin on CFU-GM proliferation. International Symposium on normal and neoplastic blood cells: from genes to therapy. Rome, 1986, June 10-13. Pag. 44.
7. Haldar C, Gupta D. Immunomodulation by the pineal gland and melatonin. Study of CFU-GM as a significant marker. 2nd Locarno Meeting on Neuroendocrinoimmunology, p. 57. Locarno 1996; May, 5-8.
8. Di Bella L, Gualano L, Rossi MT, Scalera G. Azione della melatonina (MLT) sulla piastrinogenesi in vitro. Boll Soc Ital Biol Sper 1979; LV: 323-6.
9. Lissoni P, Pittalis S, Brivio F et al. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2. Cancer 1993; 71: 2076-81.
10. Maestroni GJM, Conti A, Lissoni P. Colony stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 1994; 54: 4740-4.
11. Wood PA, Martynowicz M, Sanchez S, Chang C, Hrushesby WJM. Circadian erythropoietin pharmacodynamics. Blood 1991; 70: 16-9.
12. Wood PA, Hrushesky WJM. Chronopharmacodynamics of hematopoietic growth factors and antitumor cytokines. In: Circadian Cancer Therapy, pp. 185-207. Hrushesky WJM (Ed). CRC Press, Boca Raton, Ann Arbor, London, Tokyo, 1994.
13. Kemeny M, Alava G, Oliver J. Improving responses in hepatoma with circadian patterned hepatic artery infusions of recombinant interleukin-2. J Immunother 1992; 12: 219-22.
14. Del Gobbo V, Libri V, Villani N, Calio R, Nistico G. Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int J Immunopharmacol 1989; 11: 567-71.
15. Regelson W, Pierpaoli W. Melatonin: a rediscovered antitumor hormone? Cancer Invest 1987; 5: 379-85.
16. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-4.
17. Maestroni GJM, Covacci V, Conti A. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res 1994; 54: 2429-32.
18. Viviani S, Negretti E, Orazi A et al. Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res 1990; 8: 347-51.
19. Di Bella L, Scalera G, Rossi MT. Melatonin: an essential factor for the treatment and recovery from leukemia and cancer. International Symposium on Melatonin, pp. 161-2. Bremen 1980; September 28-30.
20. Scalera G, Rossi MT, Di Bella L, Gualano L. Red blood cell generation and melatonin. International Symposium on Melatonin, pp. 175-6. Bremen 1980; September 28-30.
21. Scalera G, Di Bella L, Rossi MT, Gualano L. Effetti della melatonina (MLT) sopra il 2,3-DPG degli eritrociti circolanti di ratto. Boll Soc Ital Biol Sper 1976; LII: 108 (abstr).
22. Di Bella L, Gualano L, Rossi MT, Scalera G. Effetti dell'azione simultanea della melatonina (MLT) e dell'ADP sui megacariociti in vitro. Boll Soc Ital Biol Sper 1979; LV: 389-93.
23. Di Bella L, Rossi MT, Scalera G. Perspectives in pineal functions. Prog Brain Res 1973; 52: 475-8.
24. Rossi MT, Di Bella L, Scalera G, Gualano L. Platelet turnover as influenced by melatonin. International Symposium on Melatonin, pp. 173-4. Bremen 1980; September 28-30.
25. Vacas MI, Del Zar MM, Martinuzzo M, Cardinali DP. Binding sites for 3H-malatonin in human platelets. J Pineal Res 1992; 13: 60-5.
26. Lissoni P, Tisi E, Brivio F, et al. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 1991; 5: 154-6.
27. Lissoni P, Barni S, Brivio F, et al. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology 1995; 52: 360-2.